Next generation radiopharmaceutical company: POINT Biopharma Global Inc. (PNT)

POINT Biopharma Global Inc. (NASDAQ: PNT), founded in 2019, is a global radiopharmaceutical company that builds a platform for clinical development and commercialization of anti-cancer radioligands. On June 30, 2021, Special purpose acquisition company Therapeutics Acquisition Corp. (Nasdaq: RACA) announced that its shareholders voted to merge with POINT Biopharma Inc., and the merged company will be renamed POINT Biopharma Global Inc.

to update: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

On December 27, 2023, Lilly Complete the acquisition of POINT Biopharma, the latter's stock Delisting 。 The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

  The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

Point Biopharma Global Inc. (PNT)

Point Biopharma Global's mission is to make radioligand therapy applicable to more cancers and available to more people, so as to improve the lives of cancer patients and their families. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

At the beginning of 2017, Dr. Neil Fleshner, a urologist in Toronto, sent his first prostate cancer patient to receive an experimental new cancer treatment - Radioligand Therapy. This treatment is not available anywhere in North America – Dr. Fleshner's patients must travel to Germany at their own expense to receive treatment. In order to enable patients to access these advances in cancer treatment, Dr. Fleshner began to consider how to form a team to build the necessary infrastructure to bring these innovative therapies to more people. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

The germination of this idea led to the creation of POINT Biopharma. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

POINT Biopharma is a global pharmaceutical company in clinical stage, committed to the development and commercialization of radioligand therapy for cancer. In addition to the radioligand molecular product line for a variety of cancers, POINT Biopharma also operates its radiopharmaceutical production facility in Indianapolis, Indiana, which can provide services for the entire North America and many places around the world. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

Point combines first-class radioactive drug assets, experienced management team, radioisotope supply, manufacturing technology and strategic partnership in new targeted treatment for patients, thus innovating treatment and diagnosis technology, drug development and commercialization of radioactive ligands. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

The income from business combination and PIPE will mainly be used for: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/point-biopharma.html

• Obtain potential regulatory approval in advance for the two candidate products PNT2002 and PNT2003 of Point's third stage products
• Promote the early development process of Point's innovative radioactive drug candidate products
• Continue to strengthen and expand internal manufacturing and logistics capabilities by completing the construction of Point's manufacturing plant in Indianapolis, Indiana

POINT Biopharma Global Inc. (PNT) is listed

On March 15, 2012, it was committed to bringing precise radiopharmaceutical therapy to cancer patients in the later stage Biopharmaceutical Company Point Biopharma Inc. and RA Capital Management Initiated Special purpose acquisition company Therapeutics Acquisition Corp. (Nasdaq: RACA) reached a business merger agreement, and the merged company will be renamed POINT Biopharma Global Inc., with a valuation of 924 million dollars.

A group of top investors have committed to participate in this transaction through about $165 million of common stock PIPE ($10 per share). Investors in PIPE include RACA sponsors RA Capital Management , Johnson&Johnson Innovation – JJDC, Inc., Surveyor Capital (part of Citadel), Farallon Capital Management, L.L.C., BVF Partners L.P., Boxer Capital, Sphera Healthcare, Woodline Partners LP, Suvretta Capital, Fairmount Funds and Perceptive Advisors 。

All shares of the current shareholders of POINT and all vested equity awards of the holders will be converted into shares of the consolidated company or equivalent awards, and the implied equity value of POINT is $585 million. The existing shareholders of RACA are converting their Class A ordinary shares into ordinary shares of the merged company in a 1:1 manner. After the merger, the common shares of the merged company are expected to be traded in the NASDAQ capital market, with the stock code of "PNT". Assuming the share price is $10 per share, the initial equity value of the consolidated company is about $924 million.

On June 30, 2021, Therapeutics Acquisition Corp. (NASDAQ: RACA) announced in an 8-K document that its shareholders approved its merger with Point Biopharma, a radioactive pharmaceutical company, at a special meeting yesterday. POINT is expected to trade on NASDAQ with the code of "PNT". RACA initially announced a US $639 million deal with POINT Biopharma on March 15.

Point Biopharma Global Inc. (PNT) US equity investment

On October 3, 2023, Lilly (Eli Lilly) (NYSE: LLY) agreed to acquire Point Biopharma Global (NASDAQ: PNT), a cancer drug developer, in cash at US $12.50 per share and a total price of US $1.4 billion. The transaction was completed on December 27, 2023.